Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Absorbing Debate: Boston Sci, Abbott Differ On Whether The Future Of Stents Is To Disappear

This article was originally published in The Gray Sheet

Executive Summary

Competing visions of the future of percutaneous coronary interventions were on display at TCT year, with Boston Scientific pushing its Synergy bioabsorbable polymer-coated, drug-eluting metal stent platform as the better long-term option to fully-resorbable scaffolds of the type Abbott is first out of the gate with.

You may also be interested in...

Abbott Launches First Fully Absorbing Stent In US Market

Abbott looks to Absorb GT1, the first fully bioresorbable coronary scaffold to gain FDA approval, to help accelerate growth. But it still has yet to be shown superior to conventional drug-eluting stents, and it also has metal stents with bioresorbable polymers to contend with.

FDA Briefing Docs Appear Positive For Abbott's Absorb, But Adverse Events Highlighted

An FDA panel meets March 15 to discuss Abbott's PMA for the firm's fully absorbable Absorb scaffold. Pre-meeting materials give a generally positive view of the device, but they highlight some elevated adverse-event rates.

Abbott’s Absorb GT1 Bioresorbable Scaffold Gets FDA Panel Date

Abbott Laboratories' Absorb GT1 Bioresorbable Vascular Scaffold System will soon be the first fully bioresorbable coronary scaffold to undergo FDA panel review. During a two-day Circulatory Systems Devices panel meeting in March, the panel will assess Absorb as well as Angel Medical System’s Angelmed Guardian System, an implantable monitor made to alert patients to coronary ischemia.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts